Thomas Goronflot

Thomas Goronflot

Auto-generated profile, based on publicly available information

Thomas Goronflot

Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, Nantes University Hospital, CHU Nantes, Nantes, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
MGMorgan Guillaudeux
Morgan Guillaudeux
OROlivia Rousseau
Olivia Rousseau
JPJulien Petot
Julien Petot
ZBZineb Bennis
Zineb Bennis
CDCharles-Axel Dein
Charles-Axel Dein
PGPierre-Antoine Gourraud
Pierre-Antoine Gourraud
While nearly all computational methods operate on pseudonymized personal data, re-identification remains a risk. With personal health data, this re-identification risk may be considered a double-crossing of patients’ trust. Herein, we present a new method to generate synthetic data of individual granularity while holding on to patients’ privacy. Developed for sensitive biomedical data, the method is patient-centric as it uses a local model to generate random new synthetic data, called an “avatar data”, for each initial sensitive individual. This method, compared with 2 other synthetic data generation techniques (Synthpop, CT-GAN), is applied to real health data with a clinical trial and a cancer observational study to evaluate the protection it provides while retaining the original statistical information. Compared to Synthpop and CT-GAN, the Avatar method shows a similar level of signal maintenance while allowing to compute additional privacy metrics. In the light of distance-based privacy metrics, each individual produces an avatar simulation that is on average indistinguishable from 12 other generated avatar simulations for the clinical trial and 24 for the observational study. Data transformation using the Avatar method both preserves, the evaluation of the treatment’s effectiveness with similar hazard ratios for the clinical trial (original HR = 0.49 [95% CI, 0.39–0.63] vs. avatar HR = 0.40 [95% CI, 0.31–0.52]) and the classification properties for the observational study (original AUC = 99.46 (s.e. 0.25) vs. avatar AUC = 99.84 (s.e. 0.12)). Once validated by privacy metrics, anonymous synthetic data enable the creation of value from sensitive pseudonymized data analyses by tackling the risk of a privacy breach.

1 September 2021 in Diabetes & Metabolism
Verified
Journal Article
Closed access
JLJean-Daniel Lalau
Jean-Daniel Lalau
AAAbdallah Al-Salameh
Abdallah Al-Salameh
SHSamy Hadjadj
Samy Hadjadj
TGThomas Goronflot
Thomas Goronflot
NWNicolas Wiernsperger
Nicolas Wiernsperger
BCBertrand Cariou
Bertrand Cariou

17 November 2020 in European Heart Journal
Verified
Journal Article
Closed access
VPVincent Probst
Vincent Probst
TGThomas Goronflot
Thomas Goronflot
SASoraya Anys
Soraya Anys
RTRomain Tixier
Romain Tixier
JBJean Briand
Jean Briand
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
Aims : Risk stratification of sudden cardiac arrest (SCA) in Brugada syndrome (Brs) remains the main challenge for physicians. Several scores have been suggested to improve risk stratification but never replicated. We aim to investigate the accuracy of the Brs risk scores. Methods and results : A total of 1613 patients [mean age 45 ± 15 years, 69% male, 323 (20%) symptomatic] were prospectively enrolled from 1993 to 2016 in a multicentric database. All data described in the risk score were double reviewed for the study. Among them, all patients were evaluated with Shanghai score and 461 (29%) with Sieira score. After a mean follow-up of 6.5 ± 4.7 years, an arrhythmic event occurred in 75 (5%) patients including 16 SCA, 11 symptomatic ventricular arrhythmia, and 48 appropriate therapies. Predictive capacity of the Shanghai score (n = 1613) and the Sieira (n = 461) score was, respectively, estimated by an area under the curve of 0.73 (0.67–0.79) and 0.71 (0.61–0.81). Considering Sieira score, the event rate at 10 years was significantly higher with a score of 5 (26.4%) than with a score of 0 (0.9%) or 1 (1.1%) (P < 0.01). No statistical difference was found in intermediate-risk patients (score 2–4). The Shanghai score does not allow to better stratify the risk of SCA. Conclusions : In the largest cohort of Brs patient ever described, risk scores do not allow stratifying the risk of arrhythmic event in intermediate-risk patient.

1 March 2021 in Diabetes & Metabolism
Verified
Journal Article
Closed access
BCBertrand Cariou
Bertrand Cariou
TGThomas Goronflot
Thomas Goronflot
ARAntoine Rimbert
Antoine Rimbert
SBSandrine Boullu
Sandrine Boullu
CMCédric Le May
Cédric Le May
SHSamy Hadjadj
Samy Hadjadj

2 February 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
RRRonan Roussel
Ronan Roussel
PDPatrice Darmon
Patrice Darmon
MPMatthieu PICHELIN
Matthieu PICHELIN
TGThomas Goronflot
Thomas Goronflot
YAYawa Abouleka
Yawa Abouleka
FIfor the CORONADO investigators
for the CORONADO investigators
Aim: To investigate the association between routine use of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and the severity of coronavirus disease 2019 (COVID‐19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID‐19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP‐4 inhibitors users vs. non‐users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results: Five hundred and ninety‐six participants were under DPP‐4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non‐users of DPP‐4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW‐adjusted models showed no significant association between the use of DPP‐4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77–1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78–1.17]). Similar neutral findings were found between use of DPP‐4 inhibitors and the risk of tracheal intubation and death. Conclusions: These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued.

6 February 2024 in Journal of Hepatology
Verified
Journal Article
Open access
MWMatthieu Wargny
Matthieu Wargny
TGThomas Goronflot
Thomas Goronflot
ARAntoine Rimbert
Antoine Rimbert
JBJérôme Boursier
Jérôme Boursier
SKSofiane Kab
Sofiane Kab
BCBertrand Cariou
Bertrand Cariou
Beyond cardiovascular disease protection, the health consequences of very low concentrations of low-density lipoprotein-cholesterol (LDL-C) remain a matter of debate. In primary hypobetalipoproteinemia (HBL), liver steatosis and cirrhosis have occasionally been reported. Here, we aimed to investigate the association between HBL and the risk of hepatic complications (cirrhosis complications and/or primary liver cancer) in the general population. A cohort study was conducted in the French population-based cohort CONSTANCES. Participants with primary HBL (LDL-C <5th percentile for age and sex, [HBL]) were compared with those with normal LDL-C concentrations (40th-60th percentile, [Control]). Participants on lipid-lowering therapies were excluded. For hepatic complications, follow-up events were compared by calculating the incidence density ratio (IDR). The same analyses were replicated in the UK Biobank (UKBB) cohort. In the CONSTANCES and UKBB cohorts, 34,653 and 94,666 patients were analyzed, with median ages of 45 and 56 years, mean LDL-C concentrations (HBL vs. control) of 71 vs. 128 mg/dl and 86 vs. 142 mg/dl, and mean follow-up durations of 5.0 and 11.5 years, respectively. The HBL group presented a higher incidence of hepatic complications than the control group: 0.32/ vs. 0.07/1,000 person-years (IDR = 4.50, 95% CI 1.91-10.6) in CONSTANCES, and 0.69/ vs. 0.21/1,000 person-years (IDR = 3.27, 95% CI 2.63-4.06) in the UKBB. This risk proved to be independent of classic risk factors for liver disease (obesity, alcohol consumption, diabetes, viral hepatitis), including in a 5-year landmark analysis excluding early events. Sensitivity analyses based on apoliprotein-B levels (instead of LDL-C levels) or genetically defined HBL showed similar results. HBL is associated with a markedly increased risk of hepatic complications. HBL must be considered as a substantial independent risk factor for liver diseases which justifies specific prevention and screening. Hypobetalipoproteinemia (HBL) is a lipid disorder characterized by permanent, inherited low levels (below the 5th percentile) of low-density lipoprotein-cholesterol. While HBL is associated with a lower risk of cardiovascular events, some studies suggest that it may be associated with a potential risk of hepatic steatosis and hepatic complications. Here, we studied the association between HBL and hepatic complications (defined as cirrhosis complications and/or primary liver cancer) in two populations of several hundred thousand people, both in France (CONSTANCES cohort) and the United Kingdom (UKBB). The results show that HBL is associated with a significant and independent excess risk of hepatic complications, including primary liver cancer. Thus, in people with HBL, the value of regular liver monitoring must be studied.